There is no evidence for or against the use of anti-inflammatory drugs such as ibuprofen for patients with COVID-19, according to a study which assessed existing studies on other coronavirus strains as well as the limited literature on the current pandemic.
According to the researchers, including those from King's College London in the UK, other types of drugs, such as TNF blockers and JAK inhibitors safe to use.
The research, published in the journal 'ecancermedicalscience', assessed 89 existing studies on other coronavirus strains such as MERS and SARS, as well as ones on the current pandemic to find out if certain medications used in people already suffering from diseases should be avoided if they catch COVID-19.
It said some patients, such as those with cancer, are already given immunosuppressive drugs to lower the body's immune response, or immunostimulant drugs to boost it.
If these patients then catch COVID-19 doctors need to know what medication to stop, the researchers explained.
"This pandemic has led to challenging decision-making about the treatment of COVID-19 patients who were already critically unwell," said Mieke Van Hemelrijck, a cancer epidemiologist and an author on the study.
"In parallel, doctors across multiple specialties are making clinical decisions about the appropriate continuation of treatments for patients with chronic illnesses requiring immune suppressive medication," Hemelrijck said.
While there had been some speculation that non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen might make the symptoms worse for some COVID-19 patients, the researchers said they did not find evidence to support this statement.
"Current evidence suggests that low dose prednisolone (a steroid used to treat allergies) and tacrolimus therapy (an immunosuppressive drug given to patients who have had an organ transplant) may have beneficial impact on the course of coronavirus infections. However further investigation is needed," said study co-author Sophie Papa.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
